CN116406299A - 用于递送mRNA疫苗的脂质纳米颗粒 - Google Patents

用于递送mRNA疫苗的脂质纳米颗粒 Download PDF

Info

Publication number
CN116406299A
CN116406299A CN202180073816.5A CN202180073816A CN116406299A CN 116406299 A CN116406299 A CN 116406299A CN 202180073816 A CN202180073816 A CN 202180073816A CN 116406299 A CN116406299 A CN 116406299A
Authority
CN
China
Prior art keywords
mrna
composition
lnp
antigen
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180073816.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·卡西米罗
S·基夫库拉
F·德罗萨
A·迪亚斯
R·L·高盛
H·R·格帕尼
K·卡尔宁
S·卡夫
A·坎穆罕默德
P·帕特尔
T·普利特尼克
A·L·萨罗德
T·蒂比茨
K·A·特兰
N·巴尔加斯蒙托亚
A·L·比尤利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority claimed from PCT/US2021/058250 external-priority patent/WO2022099003A1/en
Publication of CN116406299A publication Critical patent/CN116406299A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180073816.5A 2020-11-06 2021-11-05 用于递送mRNA疫苗的脂质纳米颗粒 Pending CN116406299A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063110965P 2020-11-06 2020-11-06
US63/110,965 2020-11-06
US202163212523P 2021-06-18 2021-06-18
US63/212,523 2021-06-18
EP21315198.8 2021-10-13
EP21315198 2021-10-13
PCT/US2021/058250 WO2022099003A1 (en) 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines

Publications (1)

Publication Number Publication Date
CN116406299A true CN116406299A (zh) 2023-07-07

Family

ID=86184333

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180073816.5A Pending CN116406299A (zh) 2020-11-06 2021-11-05 用于递送mRNA疫苗的脂质纳米颗粒

Country Status (9)

Country Link
EP (1) EP4240335A1 (https=)
JP (1) JP7817257B2 (https=)
KR (1) KR20230104223A (https=)
CN (1) CN116406299A (https=)
AU (1) AU2021374976A1 (https=)
CA (1) CA3194325A1 (https=)
CO (1) CO2023005218A2 (https=)
IL (1) IL302631A (https=)
MX (1) MX2023005203A (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119746089A (zh) * 2025-03-07 2025-04-04 细胞生态海河实验室 脂质纳米颗粒冷冻保护剂
WO2025092866A1 (zh) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗
CN120053395A (zh) * 2023-11-30 2025-05-30 苏州维益生物科技有限公司 含二硫键的核酸-脂质颗粒、药物、用途、及制备方法
CN121466311A (zh) * 2026-01-09 2026-02-06 羿美诚健(上海)生物医药有限公司 一种脂质组合物及其在核酸递送中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
WO2024097874A1 (en) * 2022-11-03 2024-05-10 Modernatx, Inc. Chemical stability of mrna
CN118021956A (zh) * 2022-11-11 2024-05-14 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
CN118021957A (zh) * 2022-11-11 2024-05-14 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
WO2025054383A1 (en) * 2023-09-06 2025-03-13 Modernatx, Inc. Chemical stability of mrna
CN118725043B (zh) * 2024-06-27 2025-12-05 中国人民解放军陆军军医大学 用于递送核酸的多肽-脂质组合物及其应用和mRNA疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160367686A1 (en) * 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US20170143848A1 (en) * 2014-03-24 2017-05-25 Shire Human Genetic Therapies, Inc. Mrna therapy for the treatment of ocular diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309002A (zh) * 2021-04-15 2023-03-01 美商轉譯生技公司 基於「古德」緩衝液的陽離子脂質

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143848A1 (en) * 2014-03-24 2017-05-25 Shire Human Genetic Therapies, Inc. Mrna therapy for the treatment of ocular diseases
US20160367686A1 (en) * 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092866A1 (zh) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗
CN120053395A (zh) * 2023-11-30 2025-05-30 苏州维益生物科技有限公司 含二硫键的核酸-脂质颗粒、药物、用途、及制备方法
CN119746089A (zh) * 2025-03-07 2025-04-04 细胞生态海河实验室 脂质纳米颗粒冷冻保护剂
CN119746089B (zh) * 2025-03-07 2025-06-13 细胞生态海河实验室 脂质纳米颗粒冷冻保护剂
CN121466311A (zh) * 2026-01-09 2026-02-06 羿美诚健(上海)生物医药有限公司 一种脂质组合物及其在核酸递送中的应用

Also Published As

Publication number Publication date
CO2023005218A2 (es) 2023-05-19
CA3194325A1 (en) 2022-05-12
AU2021374976A1 (en) 2023-06-29
JP2023550600A (ja) 2023-12-04
JP7817257B2 (ja) 2026-02-18
IL302631A (en) 2023-07-01
EP4240335A1 (en) 2023-09-13
KR20230104223A (ko) 2023-07-07
MX2023005203A (es) 2023-07-13

Similar Documents

Publication Publication Date Title
US11771653B2 (en) Lipid nanoparticles for delivering mRNA vaccines
JP7817257B2 (ja) ｍＲＮＡワクチンを送達するための脂質ナノ粒子
US20230043128A1 (en) Multivalent influenza vaccines
CN101616687B (zh) 非特异性免疫刺激剂
KR20240107146A (ko) 호흡기 세포융합 바이러스 rna 백신
KR20240118798A (ko) 인간 메타뉴모바이러스 백신
WO2025003756A2 (en) Multivalent influenza mrna vaccines
CN117580568A (zh) 多价流感疫苗
RU2860421C2 (ru) ЛИПИДНЫЕ НАНОЧАСТИЦЫ ДЛЯ ДОСТАВКИ mRNA-ВАКЦИНЫ
HK40096671A (zh) 用於递送mrna疫苗的脂质纳米颗粒
WO2024131726A1 (zh) 一种广谱流感mRNA疫苗
CN121057591A (zh) 组合呼吸道mRNA疫苗
CN121463960A (zh) 一种含有阳离子脂质的药物组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096671

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250428

Address after: Pennsylvania, USA

Applicant after: SANOFI PASTEUR

Country or region after: U.S.A.

Address before: Paris France

Applicant before: Sai Nuofei

Country or region before: France

CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Pennsylvania, USA

Applicant after: Sanofi Vaccines USA

Address before: Pennsylvania, USA

Applicant before: SANOFI PASTEUR

Country or region before: U.S.A.